Boston Trust Walden Corp Lowers Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Boston Trust Walden Corp decreased its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 40.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 899,061 shares of the biotechnology company's stock after selling 614,914 shares during the period. Boston Trust Walden Corp owned 0.86% of Corcept Therapeutics worth $45,304,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. State Street Corp lifted its stake in Corcept Therapeutics by 0.6% during the third quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company's stock valued at $162,871,000 after buying an additional 19,893 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Corcept Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,378,758 shares of the biotechnology company's stock valued at $110,108,000 after acquiring an additional 99,470 shares in the last quarter. FMR LLC grew its position in Corcept Therapeutics by 24.6% during the 3rd quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company's stock worth $63,122,000 after purchasing an additional 269,074 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in Corcept Therapeutics by 40.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,223,781 shares of the biotechnology company's stock valued at $56,637,000 after purchasing an additional 352,947 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Corcept Therapeutics by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,026,487 shares of the biotechnology company's stock valued at $47,506,000 after purchasing an additional 53,191 shares in the last quarter. 93.61% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Corcept Therapeutics news, insider Sean Maduck sold 20,000 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total value of $1,007,800.00. Following the sale, the insider now owns 85,318 shares in the company, valued at $4,299,174.02. This represents a 18.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.88, for a total transaction of $131,736.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,011 shares of company stock worth $1,461,568. Corporate insiders own 20.50% of the company's stock.

Corcept Therapeutics Trading Down 0.6 %

Shares of NASDAQ CORT traded down $0.41 during mid-day trading on Thursday, hitting $68.04. The company's stock had a trading volume of 888,167 shares, compared to its average volume of 890,669. The company's fifty day simple moving average is $56.54 and its 200-day simple moving average is $47.71. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The stock has a market cap of $7.13 billion, a price-to-earnings ratio of 54.00 and a beta of 0.58. Corcept Therapeutics Incorporated has a one year low of $20.84 and a one year high of $71.29.

Wall Street Analyst Weigh In

A number of research analysts recently commented on CORT shares. Canaccord Genuity Group boosted their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a "buy" rating in a research report on Thursday, January 30th. StockNews.com downgraded Corcept Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 25th. Sandler O'Neill reiterated a "buy" rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Finally, HC Wainwright reissued a "buy" rating and issued a $80.00 target price on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $88.25.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.